The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.
 
Sajeve Samuel Thomas
Speakers' Bureau - Amgen; Bms; Genentech; ipsen; Merck; Novartis; Pfizer
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Regeneron (Inst)
 
Bernard Doger
No Relationships to Disclose
 
Simon Haefliger
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst)
 
Juan Martin-Liberal
Consulting or Advisory Role - Bristol-Myers Squibb; Highlight Therapeutics; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Pierre Fabre; Roche
 
Zelanna Goldberg
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Alex Cacovean
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie/Pharmacyclics; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Rana Fiaz
Employment - Abbvie; Iovance Biotherapeutics
 
Guang Chen
Employment - Iovance Biotherapeutics; Johnson & Johnson (I)
Stock and Other Ownership Interests - Iovance Biotherapeutics; Johnson & Johnson (I)
 
Madan H. Jagasia
Employment - Iovance Biotherapeutics
Stock and Other Ownership Interests - Iovance Biotherapeutics
Consulting or Advisory Role - Kadmon
 
Friedrich Graf Finckenstein
Employment - Adverum (I); Iovance Biotherapeutics; Roche/Genentech; Roche/Genentech (I)
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Adverum (I); Bristol-Myers Squibb; Iovance Biotherapeutics; Johnson & Johnson (I); Roche/Genentech
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Roche/Genentech (I)
 
Maria Fardis
Employment - Acerta Pharma; Iovance Biotherapeutics
Leadership - Acerta Pharma; Iovance Biotherapeutics
Stock and Other Ownership Interests - Abbvie; Acerta Pharma; Gilead Sciences; Iovance Biotherapeutics; Kartos Therapeutics
Patents, Royalties, Other Intellectual Property - Acerta Pharma (Inst); Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; Iovance Biotherapeutics
 
Antonio Jimeno
Stock and Other Ownership Interests - Champions Oncology; Suvica
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cantargia AB (Inst); Celldex (Inst); Debiopharm Group (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); KHAR Medical (Inst); Kinex (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Roche (Inst); SQZ Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Suvica